Literature DB >> 10397596

Pharmacodynamics and toxicodynamics of drug action: signaling in cell survival and cell death.

A N Kong1, S Mandlekar, R Yu, W Lei, A Fasanmande.   

Abstract

In therapeutic response to drugs, the plasma concentration range leads to the establishment of a safe and effective dosage regimen. Our hypothesis is that by studying drug concentration-dependent effect on signal transduction mechanisms, a better understanding of the beneficial pharmacodynamic and adverse toxicodynamic responses elicited by the drug may be achieved. Using two classes of chemopreventive compounds (phenolic antioxidants and isothiocyanates), we illustrate the potential utility of two signal transduction pathways elicited by these agents to predict the pharmacodynamic effect (induction of Phase II drug metabolizing enzymes) and the potential toxicodynamic response (stimulation of caspase activity and cytotoxic cell death). At lower concentration, phenolic antioxidants and isothiocyanates activate mitogen-activated protein kinase (MAPK; extracellular signal-regulated protein kinase 2, ERK2; and c-Jun N-terminal kinase 1, JNK1) in a concentration-and time-dependent manner. The activation of MAPK by these compounds may lead to the induction of cell survival/protection genes such as c-jun, c-fos, or Phase II drug metabolizing enzymes. However, at higher concentrations, these agents activate another signaling molecule, ICE/Ced3 cysteine protease enzymes (caspases) leading to apoptotic cell death. The activation of these pathways may dictate the fate of the cells/tissues upon exposure to drugs or chemicals. At lower concentrations, these compounds activate MAPK leading to the induction of Phase II genes, which may protect the cells/tissues against toxic insults and therefore may enhance cell survival. On the other hand, at higher concentrations, these agents may activate the caspases, which may lead to apoptotic cell death, and have toxicity. Understanding the activation of these and other signal transduction events elicited by various drugs and chemicals may yield insights into the regulation of gene expression of drug metabolizing enzymes and cytotoxicity. Thus, the study of signaling events in cell survival (hemeostasis) and cell death (cytotoxicity) may have practical application during pharmaceutical drug development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10397596     DOI: 10.1023/a:1011953431486

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  112 in total

Review 1.  Signal transduction through lipid second messengers.

Authors:  S Spiegel; D Foster; R Kolesnick
Journal:  Curr Opin Cell Biol       Date:  1996-04       Impact factor: 8.382

2.  Induction of apoptosis and activation of interleukin 1beta-converting enzyme/Ced-3 protease (caspase-3) and c-Jun NH2-terminal kinase 1 by benzo(a)pyrene.

Authors:  W Lei; R Yu; S Mandlekar; A N Kong
Journal:  Cancer Res       Date:  1998-05-15       Impact factor: 12.701

3.  Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.

Authors:  M Hibi; A Lin; T Smeal; A Minden; M Karin
Journal:  Genes Dev       Date:  1993-11       Impact factor: 11.361

Review 4.  Regulation of Ras-mediated signalling: more than one way to skin a cat.

Authors:  B M Burgering; J L Bos
Journal:  Trends Biochem Sci       Date:  1995-01       Impact factor: 13.807

5.  Regulation of CYP4A1 and peroxisome proliferator-activated receptor alpha expression by interleukin-1beta, interleukin-6, and dexamethasone in cultured fetal rat hepatocytes.

Authors:  J H Parmentier; H Schohn; M Bronner; L Ferrari; A M Batt; M Dauça; P Kremers
Journal:  Biochem Pharmacol       Date:  1997-10-15       Impact factor: 5.858

6.  Role of the stress-activated/c-Jun NH2-terminal protein kinase pathway in the cellular response to adriamycin and other chemotherapeutic drugs.

Authors:  M T Osborn; T C Chambers
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

7.  An osmosensing signal transduction pathway in yeast.

Authors:  J L Brewster; T de Valoir; N D Dwyer; E Winter; M C Gustin
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

8.  A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells.

Authors:  J Han; J D Lee; L Bibbs; R J Ulevitch
Journal:  Science       Date:  1994-08-05       Impact factor: 47.728

9.  Signaling pathways in the induction of c-fos and c-jun proto-oncogenes by 3-methylcholanthrene.

Authors:  E Ainbinder; S Bergelson; V Daniel
Journal:  Recept Signal Transduct       Date:  1997

10.  Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz.

Authors:  T M Buetler; E P Gallagher; C Wang; D L Stahl; J D Hayes; D L Eaton
Journal:  Toxicol Appl Pharmacol       Date:  1995-11       Impact factor: 4.219

View more
  6 in total

Review 1.  Drug Adverse Reaction Target Database (DART) : proteins related to adverse drug reactions.

Authors:  Zhi Liang Ji; Lian Yi Han; Chun Wei Yap; Li Zhi Sun; Xin Chen; Yu Zong Chen
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

2.  Investigation of a cellular pharmacodynamic model exhibiting sharp response sensitivity and tolerance.

Authors:  Ronald A Siegel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-12-12       Impact factor: 2.745

3.  Pharmacokinetics and Pharmacodynamics of the Triterpenoid Ursolic Acid in Regulating the Antioxidant, Anti-inflammatory, and Epigenetic Gene Responses in Rat Leukocytes.

Authors:  Chengyue Zhang; Chao Wang; Wenji Li; Renyi Wu; Yue Guo; David Cheng; Yuqing Yang; Ioannis P Androulakis; Ah-Ng Kong
Journal:  Mol Pharm       Date:  2017-10-25       Impact factor: 4.939

4.  MicroRNAs: New players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways.

Authors:  Chengyue Zhang; Limin Shu; Ah-Ng Tony Kong
Journal:  Curr Pharmacol Rep       Date:  2015-01-11

Review 5.  Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression.

Authors:  Jong Hun Lee; Tin Oo Khor; Limin Shu; Zheng-Yuan Su; Francisco Fuentes; Ah-Ng Tony Kong
Journal:  Pharmacol Ther       Date:  2012-10-03       Impact factor: 12.310

Review 6.  Epigenetics/Epigenomics and Prevention of Early Stages of Cancer by Isothiocyanates.

Authors:  Rasika Hudlikar; Lujing Wang; Renyi Wu; Shanyi Li; Rebecca Peter; Ahmad Shannar; Pochung Jordan Chou; Xia Liu; Zhigang Liu; Hsiao-Chen Dina Kuo; Ah-Ng Kong
Journal:  Cancer Prev Res (Phila)       Date:  2020-10-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.